(USD) | Jun 2023 | Q/Q |
---|---|---|
Revenue | 13MM | +1% |
Gross Profit | 1.8MM | -64% |
Cost Of Revenue | 11.2MM | +45% |
Operating Income | -12.3MM | +31% |
Operating Expenses | 14.1MM | -3% |
Net Income | -13MM | +36% |
R&D | 2.2MM | -12% |
G&A | 7.9MM | +13% |
Marketing | 4.1MM | -20% |
Interest Expense | 668K | +5% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
A medical device firm with ties to Duke University has completed its acquisition of a company that had been faltering.
Combination Creates the World’s Preeminent Producer of Personalized Orthopedic Medical Devices, with Unmatched Additive Manufacturing CapabilitiesDURHAM, North Carolina and BILLERICA, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- restor3d, Inc. and Conformis, Inc. announced today that restor3d has completed its previously announced acquisition of Conformis following the approval of Conformis’ stockholders at a special meeting held on August 31, 2023. In connection with the completion of the acquisit
BILLERICA, Mass., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical technology company featuring personalized knee and hip replacement products, announced today that leading independent proxy advisory firms, Institutional Shareholder Services Inc. (“ISS”) and Glass Lewis & Co., LLC (“Glass Lewis”), have each recommended that Conformis stockholders vote “FOR” the pending merger transaction with restor3d. As previously announced, under the terms of the definitive m
BILLERICA, Mass., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical technology company featuring personalized knee and hip replacement products, announced today that leading independent proxy advisory firm, Institutional Shareholder Services Inc. (“ISS”), has recommended that Conformis stockholders vote “FOR” the pending merger transaction with restor3d. As previously announced, under the terms of the definitive merger agreement, restor3d will acquire all outstan
ConforMIS (CFMS) delivered earnings and revenue surprises of -34.85% and 2.71%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
BILLERICA, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the second quarter ended June 30, 2023. Second Quarter 2023 Summary Total revenue of $13.0 million, a decrease of 15% year-over-year on a reported and constant currency basis.Product revenue of $12.5 million, a decrease of 17% year-over-year on a reported and constant currency ba
Conformis, Inc. ( NASDAQ:CFMS ) shareholders would be excited to see that the share price has had a great month...
Combination creates a leading personalized 3D-printed orthopedic medical device companyDURHAM, N.C. and BILLERICA, Mass., June 22, 2023 (GLOBE NEWSWIRE) -- restor3d, Inc. and Conformis, Inc. (NASDAQ: CFMS) announced today that they have entered into a definitive merger agreement under which restor3d, a leading personalized 3D-printed orthopedic company, will acquire all outstanding shares of common stock of Conformis at $2.27 per share in cash, which represents an approximate 96 percent premium
Conformis, Inc. (NASDAQ:CFMS) Q1 2023 Earnings Call Transcript May 8, 2023 Conformis, Inc. beats earnings expectations. Reported EPS is $-1.32, expectations were $-1.39. Operator: Good morning, and welcome to the First Quarter 2023 Earnings Conference Call for Conformis, Incorporated. My name is Tanya, and I will be your conference operator today. All lines have been […]
ConforMIS (CFMS) delivered earnings and revenue surprises of 15.38% and 2.37%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?